Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
6.86M
-
Shares change
-
-557K
-
Total reported value, excl. options
-
$55.1M
-
Value change
-
-$6.26M
-
Number of buys
-
12
-
Number of sells
-
-35
-
Price
-
$8.03
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q2 2021
57 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q2 2021.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.86M shares
.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (3.22M shares), Polaris Venture Management Co. V, L.L.C. (1.1M shares), Ikarian Capital, LLC (625K shares), PURA VIDA INVESTMENTS, LLC (543K shares), VANGUARD GROUP INC (220K shares), Soleus Capital Management, L.P. (183K shares), MILLENNIUM MANAGEMENT LLC (155K shares), ArrowMark Colorado Holdings LLC (139K shares), BOOTHBAY FUND MANAGEMENT, LLC (83.2K shares), and DEUTSCHE BANK AG\ (76.4K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.